The Pharma Letter » Biosimilars
The Pharma Letter » Biosimilars
3 FOLLOWERS
Scan through our blog and get to know about biosimilars. The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment, and analysis for the pharmaceutical, biotechnology, and generics sectors of the healthcare industry, backed by a team of respected writers with many years of experience in the field.
EC approval for Pfizer’s Emblaveo in multidrug-resistant infections
The Pharma Letter » Biosimilars
by
1w ago
..read more
Visit website
EC approval for Pyzchiva, a biosimilar of Stelara
The Pharma Letter » Biosimilars
by
1w ago
..read more
Visit website
FDA updates on CAR-T cell therapies label changes
The Pharma Letter » Biosimilars
by
1w ago
..read more
Visit website
The week in pharma: action, reaction and insight – week to April 19, 2024
The Pharma Letter » Biosimilars
by
1w ago
..read more
Visit website
US seniors pay more for generic meds while prices continue to fall
The Pharma Letter » Biosimilars
by
1w ago
..read more
Visit website
New long-term efficacy and safety data on KarXT in schizophrenia
The Pharma Letter » Biosimilars
by
3w ago
..read more
Visit website
UB start-up Abceutics acquired by Merck
The Pharma Letter » Biosimilars
by
3w ago
..read more
Visit website
Top-Line results from Phase III Study of Pfizer’s Abrysvo
The Pharma Letter » Biosimilars
by
3w ago
..read more
Visit website
PBM rebate schemes to suppress biosimilar Humira cost US patients $6 billion
The Pharma Letter » Biosimilars
by
3w ago
..read more
Visit website
Recognition for value added medicines, real-world evidence and Chinese innovation are pharma’s key themes of the moment, Pharmanovia boss says
The Pharma Letter » Biosimilars
by
2M ago
..read more
Visit website

Follow The Pharma Letter » Biosimilars on FeedSpot

Continue with Google
Continue with Apple
OR